Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells $77,220.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 4,290 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $18.00, for a total value of $77,220.00. Following the completion of the transaction, the chief financial officer owned 216,637 shares of the company’s stock, valued at approximately $3,899,466. This represents a 1.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kyle Piskel also recently made the following trade(s):

• On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.50, for a total transaction of $3,174,990.00.
• On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.05, for a total value of $3,343.90.

Adaptive Biotechnologies Stock Down 0.2%

Shares of ADPT traded down $0.03 during midday trading on Wednesday, hitting $18.04. The company had a trading volume of 1,865,999 shares, compared to its average volume of 1,982,211. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -33.41 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76. The company’s 50 day moving average price is $16.50 and its 200 day moving average price is $14.44.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. During the same period last year, the firm posted ($0.22) EPS. The company’s revenue for the quarter was up 102.4% on a year-over-year basis. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ADPT. Piper Sandler lifted their price target on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. raised their target price on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. Guggenheim began coverage on Adaptive Biotechnologies in a research note on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Morgan Stanley began coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Institutional Trading of Adaptive Biotechnologies

Large investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. lifted its stake in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Adaptive Biotechnologies by 15.6% in the 2nd quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock valued at $37,461,000 after purchasing an additional 434,347 shares during the period. Aristotle Atlantic Partners LLC increased its holdings in shares of Adaptive Biotechnologies by 8.6% in the 3rd quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock valued at $46,776,000 after purchasing an additional 247,402 shares during the period. Fred Alger Management LLC lifted its position in shares of Adaptive Biotechnologies by 6.7% in the third quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock worth $37,613,000 after purchasing an additional 158,807 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after purchasing an additional 2,062,282 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.